TOP TIERMARKET NEWSWIRE
Movers explained · November 5, 2026

Why Is NUVATION BIO INC A Class A (NUVB) Stock Moving Today?

By the Top Tier Newswire AI Desk · August 19, 2026 at 12:22 AM ET · reviewed against 10 wire stories

NUVATION BIO INC A Class A (NUVB) is drawing unusual attention today. Our newswire has captured 10 stories on NUVB across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 52/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Why NUVB stock is up today

Nuvation Bio Inc. (NUVB) rose 7.41% to $6.96 on Monday, driven by a new initiation of coverage from J.P. Morgan. The firm assigned the stock an Overweight rating, citing a strong launch trajectory for the company’s lead drug, Ibtrozi. This move has drawn attention from multiple financial analysts and is reflected in a broader coverage shift toward the stock.

What Happened

J.P. Morgan initiated coverage of Nuvation Bio with an Overweight rating, signaling confidence in the company’s near-term prospects. The firm highlighted the potential of Ibtrozi, a targeted cancer therapy, and its expected market entry. This followed similar positive ratings from RBC Capital and HC Wainwright & Co., which also raised price targets for the stock. Nuvation Bio recently reported second-quarter results that beat revenue and EPS estimates, adding to the positive momentum. The company also announced that new data from its Phase 2 trials for Ibtrozi in ROS1+ NSCLC will be presented at major oncology conferences, including WCLC and ESMO.

What The Data Shows

Nuvation Bio’s stock has shown mixed performance over the past eight sessions, falling 5.0% from $6.37 to $6.05 before Monday’s sharp rebound. The stock currently trades within its 52-week range of $2.57 to $9.75. On August 19, the stock printed 14 fresh 52-week highs and 15 fresh 52-week lows, indicating heightened volatility. Recent insider transactions show three separate sales totaling $1.4 million by senior executives, including the CFO, Chief People Officer, and Chief Regulatory Officer. These sales occurred on June 23, 2026, and were reported via SEC Form 4. Over the last 90 days, insiders have sold $1.4 million in shares, while only $118,000 worth of shares were purchased.

What To Watch

Nuvation Bio is not scheduled to report earnings in the near term. Investors should monitor the breadth of analyst coverage and any updates on the regulatory or clinical progress of Ibtrozi, particularly ahead of its presentation at WCLC and ESMO.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

NUVB by the numbers

7 sessions: +6.21%Coverage: 10 stories / 6 sourcesAI sentiment: 52/100 (mixed)Mkt cap: $2.1B52w: $2.57 to $9.75
NUVB · Aug 19 session (5-min) · +4.45% vs prior close · updated 8:57 PM ET
$6.93$7.24$7.55prev close $6.96$7.277:00 AM10:05 AM1:10 PM4:15 PM7:20 PM7:00 AM · $7.057:05 AM · $7.077:10 AM · $7.067:20 AM · $7.097:25 AM · $7.067:30 AM · $7.077:35 AM · $7.057:40 AM · $7.057:55 AM · $7.048:00 AM · $7.058:05 AM · $7.038:10 AM · $7.058:15 AM · $7.078:20 AM · $7.068:25 AM · $7.078:30 AM · $7.088:35 AM · $7.118:40 AM · $7.168:45 AM · $7.198:50 AM · $7.248:55 AM · $7.209:00 AM · $7.199:05 AM · $7.199:10 AM · $7.209:15 AM · $7.209:20 AM · $7.189:25 AM · $7.219:30 AM · $7.049:35 AM · $7.119:40 AM · $7.129:45 AM · $7.179:50 AM · $7.289:55 AM · $7.2910:00 AM · $7.3410:05 AM · $7.3810:10 AM · $7.3810:15 AM · $7.3810:20 AM · $7.4010:25 AM · $7.5110:30 AM · $7.4810:35 AM · $7.4910:40 AM · $7.4210:45 AM · $7.4110:50 AM · $7.5010:55 AM · $7.4111:00 AM · $7.4911:05 AM · $7.5011:10 AM · $7.4911:15 AM · $7.3911:20 AM · $7.3611:25 AM · $7.3611:30 AM · $7.2511:35 AM · $7.2111:40 AM · $7.2411:45 AM · $7.2511:50 AM · $7.2111:55 AM · $7.2012:00 PM · $7.2112:05 PM · $7.2412:10 PM · $7.2112:15 PM · $7.2112:20 PM · $7.2612:25 PM · $7.2412:30 PM · $7.2212:35 PM · $7.2112:40 PM · $7.2212:45 PM · $7.2512:50 PM · $7.2812:55 PM · $7.261:00 PM · $7.291:05 PM · $7.301:10 PM · $7.321:15 PM · $7.321:20 PM · $7.291:25 PM · $7.271:30 PM · $7.321:35 PM · $7.301:40 PM · $7.311:45 PM · $7.301:50 PM · $7.331:55 PM · $7.302:00 PM · $7.332:05 PM · $7.292:10 PM · $7.282:15 PM · $7.272:20 PM · $7.292:25 PM · $7.292:30 PM · $7.302:35 PM · $7.292:40 PM · $7.252:45 PM · $7.262:50 PM · $7.252:55 PM · $7.253:00 PM · $7.273:05 PM · $7.343:10 PM · $7.373:15 PM · $7.383:20 PM · $7.373:25 PM · $7.343:30 PM · $7.353:35 PM · $7.353:40 PM · $7.393:45 PM · $7.363:50 PM · $7.293:55 PM · $7.254:00 PM · $7.284:10 PM · $7.274:15 PM · $7.254:40 PM · $7.234:45 PM · $7.294:50 PM · $7.295:05 PM · $7.285:20 PM · $7.285:30 PM · $7.275:35 PM · $7.266:15 PM · $7.296:20 PM · $7.266:30 PM · $7.266:35 PM · $7.277:00 PM · $7.277:15 PM · $7.267:20 PM · $7.27
AI sentiment, last 36h · averaged over 10 stories · 52/100 neutral
AI sentiment 52/100 (neutral)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 10 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agonowPR Newswire · sentiment 64 · Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdatePR Newswire · 64Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdateSEC 8-K · sentiment 50 · Nuvation Bio Inc. (NUVB) files 8-KSEC 8-K · 50Nuvation Bio Inc. (NUVB) files 8-KSeeking Alpha · sentiment 58 · Nuvation Bio GAAP EPS of -$0.12 in-line, revenue of $45M beats by $10.58MSeeking Alpha · 58Nuvation Bio GAAP EPS of -$0.12 in-line, revenue of $45M beats by $10.58MGuruFocus · sentiment 38 · Nuvation Bio Inc Reports Q3 2026 Revenue of $45.0 Million; Net Loss of $(0.12) Per Share Slightly Misses EstimatesGuruFocus · 38Nuvation Bio Inc Reports Q3 2026 Revenue of $45.0 Million; Net Loss of $(0.12) Per Share …Seeking Alpha · sentiment 50 · Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call TranscriptSeeking Alpha · 50Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call TranscriptSeeking Alpha · sentiment 63 · Nuvation Bio outlines potential Europe approval in first half of next year with ~$30M milestone, as IBTROZI posts 18% sequential growthSeeking Alpha · 63Nuvation Bio outlines potential Europe approval in first half of next year with ~$30M mil…GuruFocus · sentiment 64 · Nuvation Bio Inc (NUVB) Q3 2026 Earnings Call Highlights: IBTROZI Revenue Climbs 18% as First-Line Share Tops 60%GuruFocus · 64Nuvation Bio Inc (NUVB) Q3 2026 Earnings Call Highlights: IBTROZI Revenue Climbs 18% as F…The Fly · sentiment 34 · Nuvation Bio price target lowered to $13 from $14 at B. RileyThe Fly · 34Nuvation Bio price target lowered to $13 from $14 at B. RileyThe Motley Fool · sentiment 58 · Nuvation Bio (NUVB) Q3 2026 Earnings Call TranscriptThe Motley Fool · 58Nuvation Bio (NUVB) Q3 2026 Earnings Call TranscriptGuruFocus · sentiment 38 · NUVB Maintains by RBC Capital -- Price Target Lowered to $17GuruFocus · 38NUVB Maintains by RBC Capital -- Price Target Lowered to $17
6h agoGuruFocusBEARISH 38Analyst

NUVB Maintains by RBC Capital -- Price Target Lowered to $17

12h agoThe Motley FoolBULLISH 58Earnings

Nuvation Bio (NUVB) Q3 2026 Earnings Call Transcript

Management weighed a European milestone and new glioma data ahead of 2027.

12h agoThe FlyBEARISH 34Analyst

Nuvation Bio price target lowered to $13 from $14 at B. Riley

17h agoGuruFocusBULLISH 64Earnings

Nuvation Bio Inc (NUVB) Q3 2026 Earnings Call Highlights: IBTROZI Revenue Climbs 18% as First-Line Share Tops 60%

Total Revenue: $45 million in Q3 2026; $159.9 million for first nine months of 2026.IBTROZI Net US Product Revenue: $27.5 million in Q3 2026, up 18% sequentiall

23h agoSeeking AlphaBULLISH 63Earnings

Nuvation Bio outlines potential Europe approval in first half of next year with ~$30M milestone, as IBTROZI posts 18% sequential growth

Nuvation Bio Q3 2026 earnings: IBTROZI growth, ROS1 market softness, safusidenib progress, and cash runway.

23h agoSeeking AlphaNEUTRAL 50Earnings

Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript

Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call November 4, 2026 4:30 PM ESTCompany ParticipantsRobert DeVita - Vice President of Corporate Development &...

1d agoGuruFocusBEARISH 38Earnings

Nuvation Bio Inc Reports Q3 2026 Revenue of $45.0 Million; Net Loss of $(0.12) Per Share Slightly Misses Estimates

1d agoSeeking AlphaBULLISH 58Earnings

Nuvation Bio GAAP EPS of -$0.12 in-line, revenue of $45M beats by $10.58M

Nuvation Bio Q3 results: revenue surged 243% to beat estimates while EPS met expectations.

1d agoSEC 8-KNEUTRAL 50General

Nuvation Bio Inc. (NUVB) files 8-K

Filed: 2026-11-04 AccNo: 0001193125-26-447321 Size: 294 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

1d agoPR NewswireBULLISH 64Earnings

Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI® (taletrectinib) IBTROZI continues to be the most prescribed ROS1 TKI and established as the ROS1 market leader in new patient starts and total active patients for both...

Frequently asked questions

Why is NUVB stock moving today?

NUVATION BIO INC A Class A (NUVB) is drawing unusual attention today. Our newswire has captured 10 stories on NUVB across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 52/100). The most recent driver: "NUVB Maintains by RBC Capital -- Price Target Lowered to $17" (GuruFocus).

Is NUVB a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of NUVB coverage reads 52/100 over 10 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.

More moves explained today

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on NUVB: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier NUVB move explainers: 2026-08-19 · 2026-08-18